FibroGen throws down the prostate cancer gauntlet
Amid doubts about early data with FG-3246, the group is scathing about its rivals.
Volastra vies for the next big synthetic lethality target
The group reckons big pharma is eyeing KIF18A inhibition, but for now there are just a handful of players.
CCR8 expectations
Blockade of CCR8 has quietly emerged as a hot oncology target, especially for anti-PD-(L)1 MAb combinations.
Boehringer: what’s in and what’s out?
A year-end pipeline update reveals Boehringer Ingelheim’s oncology priorities.
Astra goes early in small cell
The group was a first mover in stage III NSCLC, and now it hopes to repeat the trick in SCLC.
Merck makes haste to catch up in KRAS
The company is setting up another battle with Bristol Myers Squibb, while Amgen has different plans.
The month ahead: April’s upcoming events
April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.
Deals mask CytomX’s fundamental problem
Another disappointment raises fresh doubts about CytomX’s extensively partnered masked therapeutics.
